MCID: DRM010
MIFTS: 64

Dermatomyositis

Categories: Rare diseases, Neuronal diseases, Nephrological diseases, Bone diseases, Skin diseases, Muscle diseases

Aliases & Classifications for Dermatomyositis

MalaCards integrated aliases for Dermatomyositis:

Name: Dermatomyositis 12 76 53 54 59 55 44 15 73
Amyopathic Dermatomyositis 12 53 73
Adult Dermatomyositis 53 59
Polymyositis with Skin Involvement 12
Dermatomyositis Sine Myositis 53
Adult Type Dermatomyositis 73
Dermatopolymyositis 12
Adm 53

Characteristics:

Orphanet epidemiological data:

59
dermatomyositis
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe),1-9/1000000 (Australia),1-9/100000 (Australia),1-9/1000000 (Argentina),1-5/10000 (Argentina),1-9/1000000 (United States),1-9/1000000 (Spain); Age of onset: All ages; Age of death: any age;

Classifications:



Summaries for Dermatomyositis

NINDS : 54 Dermatomyositis is one of a group of muscle diseases known as the inflammatory myopathies, which are characterized by chronic muscle inflammation accompanied by muscle weakness.  Dermatomyositis’ cardinal symptom is a skin rash that precedes, accompanies, or follows  progressive muscle weakness.  The rash looks patchy, with purple or red discolorations, and characteristically develops on the eyelids and on muscles used to extend or straighten joints, including knuckles, elbows, knees, and toes.  Red rashes may also occur on the face, neck, shoulders, upper chest, back, and other locations, and there may be swelling in the affected areas.  The rash sometimes occurs without obvious muscle involvement.  Adults with dermatomyositis may experience weight loss, a low-grade fever, inflamed lungs, and be sensitive to light such that the rash or muscle disease gets worse.  Children and adults with dermatomyositis may develop calcium deposits, which appear as hard bumps under the skin or in the muscle (called calcinosis).  Calcinosis most often occurs 1-3 years after the disease begins.  These deposits are seen more often in children with dermatomyositis than in adults.  In some cases of dermatomyositis, distal muscles (muscles located away from the trunk of the body, such as those in the forearms and around the ankles and wrists) may be affected as the disease progresses.  Dermatomyositis may be associated with collagen-vascular or autoimmune diseases, such as lupus. 

MalaCards based summary : Dermatomyositis, also known as amyopathic dermatomyositis, is related to polymyositis and psoriasis, and has symptoms including exanthema and pruritus. An important gene associated with Dermatomyositis is RN7SL1 (RNA, 7SL, Cytoplasmic 1
Autoantibodies against signal recognition particle (SRP) are detected in patients with polymyositis/dermatomyositis (PM/DM). The SRP consists of 7SL RNA and 6 protein components.
Dysfunction Pattern: Interaction), and among its related pathways/superpathways are MicroRNAs in cancer and miRNAs involved in DNA damage response. The drugs Pirfenidone and Abatacept have been mentioned in the context of this disorder. Affiliated tissues include muscle or, skin and lung, and related phenotypes are chondrocalcinosis and dry skin

NIH Rare Diseases : 53 Amyopathic dermatomyositis is a form of dermatomyositis characterized by the presence of typical skin findings without muscle weakness. Some of the skin changes that suggest dermatomyositis include a pink rash on the face, neck, forearms and upper chest; Gottron's papules and heliotrope eyelids. Pruritis and photosensitivity are common, as is scalp inflammation and thinning of the hair. While patients with amyopathic dermatomyositis should not have clinically evident muscle weakness, minor muscle abnormalities may be included. Fatigue is reported in at least 50% of patients. Some cases have been associated with internal malignancy and/or interstitial lung disease. Treatment may include sun avoidance, ample use of sunscreen, topical corticosteroids, antimalarial agents, methotrexate, mycophenolate mofetil, or intravenous (IV) immunoglobulin.

Disease Ontology : 12 A myositis that results in inflammation located in muscle or located in skin where a skin rash is often seen prior to the onset of muscle weakness. The disease may result from either a viral infection or an autoimmune reaction.

Wikipedia : 76 Dermatomyositis (DM) is a long term inflammatory disorder which affects muscles. Its symptoms are... more...

Related Diseases for Dermatomyositis

Diseases in the Dermatomyositis family:

Adult Dermatomyositis

Diseases related to Dermatomyositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 333)
# Related Disease Score Top Affiliating Genes
1 polymyositis 29.0 MIR132 MIR146B MIR21 MIR210 MIR222 MIR362
2 psoriasis 28.9 MIR146B MIR21 MIR381 MIR99B
3 melanoma 28.9 MIR154 MIR199B MIR210 MIR221 MIR222 MIR34A
4 gastric cancer 28.3 MIR21 MIR214 MIR221 MIR222 MIR223 MIR34A
5 ovarian cancer 28.2 MIR146B MIR21 MIR210 MIR214 MIR221 MIR222
6 inclusion body myositis 28.1 MIR146B MIR21 MIR214 MIR221 MIR222 MIR223
7 lung cancer 27.3 MIR146B MIR148A MIR199B MIR21 MIR210 MIR214
8 pancreatic cancer 26.8 MIR148A MIR148B MIR21 MIR210 MIR214 MIR221
9 hepatocellular carcinoma 26.2 MIR132 MIR148A MIR148B MIR199B MIR21 MIR214
10 prostate cancer 26.2 MIR148A MIR199B MIR21 MIR210 MIR214 MIR221
11 muscular dystrophy, duchenne type 23.4 MIR146B MIR148A MIR154 MIR199B MIR210 MIR221
12 childhood type dermatomyositis 12.6
13 adult dermatomyositis 12.2
14 neonatal dermatomyositis 12.0
15 complement component 9 deficiency 11.6
16 myositis 11.5
17 hypertension, essential 11.3
18 idiopathic inflammatory myopathy 11.2
19 antisynthetase syndrome 11.2
20 cryptogenic organizing pneumonia 11.2
21 ovarian serous carcinoma 10.7 MIR21 MIR214
22 lung disease 10.5
23 interstitial lung disease 10.5
24 diffuse large b-cell lymphoma 10.4 MIR21 MIR210 MIR221
25 muscular dystrophy, becker type 10.4 MIR146B MIR221
26 calcinosis 10.4
27 lupus erythematosus 10.2
28 pneumonia 10.2
29 glioblastoma multiforme 10.1 MIR132 MIR21 MIR210 MIR221
30 systemic lupus erythematosus 10.1
31 myopathy 10.1
32 arthritis 10.1
33 panniculitis 10.0
34 lymphoma 10.0
35 pituitary adenoma 10.0 MIR132 MIR223
36 rheumatoid arthritis 10.0
37 type i 10.0
38 breast cancer 9.9
39 adenocarcinoma 9.9
40 juvenile overlap myositis 9.9
41 cutaneous lupus erythematosus 9.9
42 pancreatic ductal adenocarcinoma 9.9 MIR148A MIR148B MIR21 MIR221 MIR223
43 leukemia, acute lymphoblastic 9.9 MIR199B MIR21 MIR210 MIR221 MIR222 MIR223
44 scleroderma, familial progressive 9.9
45 nasopharyngeal carcinoma 9.9
46 nasopharyngitis 9.9
47 connective tissue disease 9.9
48 vasculitis 9.9
49 fasciitis 9.9
50 leiomyoma, uterine 9.9 MIR21 MIR34A

Comorbidity relations with Dermatomyositis via Phenotypic Disease Network (PDN):


Acute Cystitis Polymyositis

Graphical network of the top 20 diseases related to Dermatomyositis:



Diseases related to Dermatomyositis

Symptoms & Phenotypes for Dermatomyositis

Human phenotypes related to Dermatomyositis:

59 32 (show top 50) (show all 51)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 chondrocalcinosis 59 32 frequent (33%) Frequent (79-30%) HP:0000934
2 dry skin 59 32 frequent (33%) Frequent (79-30%) HP:0000958
3 pruritus 59 32 frequent (33%) Frequent (79-30%) HP:0000989
4 cutaneous photosensitivity 59 32 occasional (7.5%) Occasional (29-5%) HP:0000992
5 acrocyanosis 59 32 frequent (33%) Frequent (79-30%) HP:0001063
6 muscular hypotonia 59 32 frequent (33%) Frequent (79-30%) HP:0001252
7 arthritis 59 32 frequent (33%) Frequent (79-30%) HP:0001369
8 abnormality of the nail 59 32 frequent (33%) Frequent (79-30%) HP:0001597
9 dysphonia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001618
10 myocardial infarction 59 32 occasional (7.5%) Occasional (29-5%) HP:0001658
11 pericarditis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001701
12 weight loss 59 32 frequent (33%) Frequent (79-30%) HP:0001824
13 fever 59 32 occasional (7.5%) Occasional (29-5%) HP:0001945
14 pulmonary arterial hypertension 59 32 occasional (7.5%) Occasional (29-5%) HP:0002092
15 respiratory insufficiency 59 32 frequent (33%) Frequent (79-30%) HP:0002093
16 recurrent respiratory infections 59 32 frequent (33%) Frequent (79-30%) HP:0002205
17 pulmonary fibrosis 59 32 frequent (33%) Frequent (79-30%) HP:0002206
18 diffuse reticular or finely nodular infiltrations 59 32 frequent (33%) Frequent (79-30%) HP:0002207
19 vasculitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0002633
20 lymphoma 59 32 occasional (7.5%) Occasional (29-5%) HP:0002665
21 arthralgia 59 32 frequent (33%) Frequent (79-30%) HP:0002829
22 autoimmunity 59 32 hallmark (90%) Very frequent (99-80%) HP:0002960
23 breast carcinoma 59 32 occasional (7.5%) Occasional (29-5%) HP:0003002
24 myalgia 59 32 hallmark (90%) Very frequent (99-80%) HP:0003326
25 emg abnormality 59 32 hallmark (90%) Very frequent (99-80%) HP:0003457
26 proximal muscle weakness 59 32 hallmark (90%) Very frequent (99-80%) HP:0003701
27 interstitial pulmonary abnormality 59 32 frequent (33%) Frequent (79-30%) HP:0006530
28 aplasia/hypoplasia of the skin 59 32 occasional (7.5%) Occasional (29-5%) HP:0008065
29 feeding difficulties in infancy 59 32 occasional (7.5%) Occasional (29-5%) HP:0008872
30 inflammatory myopathy 59 32 hallmark (90%) Very frequent (99-80%) HP:0009071
31 erythema 59 32 hallmark (90%) Very frequent (99-80%) HP:0010783
32 abnormal hair quantity 59 32 frequent (33%) Frequent (79-30%) HP:0011362
33 sinus tachycardia 59 32 occasional (7.5%) Occasional (29-5%) HP:0011703
34 fatigue 59 32 frequent (33%) Frequent (79-30%) HP:0012378
35 myocarditis 59 32 occasional (7.5%) Occasional (29-5%) HP:0012819
36 lung adenocarcinoma 59 32 occasional (7.5%) Occasional (29-5%) HP:0030078
37 periorbital edema 59 32 hallmark (90%) Very frequent (99-80%) HP:0100539
38 telangiectasia of the skin 59 32 occasional (7.5%) Occasional (29-5%) HP:0100585
39 cellulitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0100658
40 gastrointestinal stroma tumor 59 32 occasional (7.5%) Occasional (29-5%) HP:0100723
41 gangrene 59 32 occasional (7.5%) Occasional (29-5%) HP:0100758
42 papule 59 32 frequent (33%) Frequent (79-30%) HP:0200034
43 skin ulcer 59 32 frequent (33%) Frequent (79-30%) HP:0200042
44 abnormality of the eyelid 59 Very frequent (99-80%)
45 edema 59 Very frequent (99-80%)
46 abnormality of the voice 59 Occasional (29-5%)
47 abnormality of eosinophils 59 Occasional (29-5%)
48 neoplasm 59 Occasional (29-5%)
49 arrhythmia 59 Occasional (29-5%)
50 abnormal eyelid morphology 32 hallmark (90%) HP:0000492

UMLS symptoms related to Dermatomyositis:


exanthema, pruritus

Drugs & Therapeutics for Dermatomyositis

Drugs for Dermatomyositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 116)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pirfenidone Approved, Investigational Phase 4 53179-13-8 40632
2
Abatacept Approved Phase 4,Phase 3,Phase 2 332348-12-6 10237
3 Analgesics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
4 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
5 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
7 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Vaccines Phase 4
10 Adrenocorticotropic Hormone Phase 4,Phase 2
11 beta-endorphin Phase 4,Phase 2
12 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
13 Hormones Phase 4,Phase 3,Phase 2,Phase 1
14 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
15 Melanocyte-Stimulating Hormones Phase 4,Phase 2
16 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17
Levoleucovorin Approved, Investigational Phase 3,Phase 2 68538-85-2
18
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
19
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
20
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2 22916-47-8 4189
21
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
22
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
23
Benzocaine Approved, Investigational Phase 2, Phase 3 1994-09-7, 94-09-7 2337
24
Tacrolimus Approved, Investigational Phase 2, Phase 3 104987-11-3 445643 439492
25
Alendronate Approved Phase 2, Phase 3 121268-17-5, 66376-36-1 2088
26
Infliximab Approved Phase 2, Phase 3 170277-31-3
27
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 50-18-0, 6055-19-2 2907
28
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
29
Etanercept Approved, Investigational Phase 2, Phase 3,Phase 1 185243-69-0
30
belimumab Approved Phase 2, Phase 3 356547-88-1 5957 10451420
31
Acetylcysteine Approved, Investigational Phase 2, Phase 3 616-91-1 12035
32
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
33
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
34 tannic acid Approved, Nutraceutical Phase 2, Phase 3
35 Antiemetics Phase 3,Phase 2
36 Antifungal Agents Phase 3,Phase 2
37 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
38 Antimetabolites Phase 3,Phase 2,Not Applicable
39 Antimetabolites, Antineoplastic Phase 3,Phase 2
40 Antineoplastic Agents, Hormonal Phase 3,Phase 2
41 Autonomic Agents Phase 3,Phase 2
42 Calcineurin Inhibitors Phase 3,Phase 2
43 Cyclosporins Phase 3,Phase 2
44 Dermatologic Agents Phase 3,Phase 2
45 Folic Acid Antagonists Phase 3,Phase 2
46 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
47 glucocorticoids Phase 3,Phase 2,Phase 1
48 Methylprednisolone acetate Phase 3,Phase 2
49 Methylprednisolone Hemisuccinate Phase 3,Phase 2
50 Neuroprotective Agents Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 88)
# Name Status NCT ID Phase Drugs
1 Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Unknown status NCT02821689 Phase 4 Pirfenidone
2 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
3 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
4 Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis Recruiting NCT02245841 Phase 4 H.P. Acthar Gel
5 Abatacept in Juvenile Dermatomyositis Recruiting NCT02594735 Phase 4 Abatacept
6 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Active, not recruiting NCT03226119 Phase 4
7 Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis Unknown status NCT00323960 Phase 3 3 MPDN pulse + PDN;3 MPDN pulse + PDN + CSA;3 MPDN pulse + PDN + MTX
8 Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM) Completed NCT00335985 Phase 3 GB-0998;Placebo of GB-0998
9 Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM Completed NCT00651040 Phase 3 Prednisone;Methotrexate
10 Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus Completed NCT00504348 Phase 2, Phase 3 Tacrolimus
11 Alendronate Osteoporosis Study Completed NCT00277251 Phase 2, Phase 3 Alendronate
12 Anakinra in Myositis Completed NCT01165008 Phase 2, Phase 3 Anakinra
13 Treatment With TNF Blockade, Infliximab, in Patients With Myositis Completed NCT00443222 Phase 2, Phase 3 Infliximab
14 Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy) Recruiting NCT02728752 Phase 3 Octagam 10%
15 Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD Recruiting NCT01862926 Phase 2, Phase 3 Rituximab;Cyclophosphamide
16 Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy Recruiting NCT02971683 Phase 3 Abatacept subcutaneous;Placebo
17 Belimumab in Myositis Recruiting NCT02347891 Phase 2, Phase 3 Belimumab;Placebo
18 Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis Terminated NCT00035958 Phase 2, Phase 3 Prednisone;Methotrexate;Etanercept
19 A Clinical Trial for CTD-ILD Treatment Terminated NCT01424033 Phase 2, Phase 3 N-Acetylcysteine
20 Abatacept Treatment in Polymyositis and Dermatomyositis Unknown status NCT01315938 Phase 2 Abatacept;Abatacept
21 Topical Sodium Thiosulfate and Fractional Carbon Dioxide Laser in Treating Dermatomyositis Associated Calcinosis Completed NCT01572844 Phase 2 Sodium thiosulfate
22 Acthar in Treatment of Refractory Dermatomyositis and Polymyositis Completed NCT01906372 Phase 2 Adrenocorticotropic Hormone Gel
23 Safety and Efficacy of BAF312 in Dermatomyositis Completed NCT02029274 Phase 2 BAF312 0.5 mg;BAF312 2 mg;BAF312 10 mg;Placebo to BAF312
24 Efficacy of an Individual Rehabilitation Program in Polymyositis and Dermatomyositis Completed NCT01415219 Phase 2
25 Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis Completed NCT00005571 Phase 2 h5G1.1-mAb
26 Methimazole to Treat Polymyositis and Dermatomyositis Completed NCT00001421 Phase 2 methimazole
27 Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis Completed NCT00033891 Phase 2 Infliximab
28 Absorption of Corticosteroids in Children With Juvenile Dermatomyositis Completed NCT00004357 Phase 2 Methylprednisolone;Prednisolone
29 Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) Completed NCT00106184 Phase 2 Rituximab;Placebo
30 Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies Completed NCT00001261 Phase 2 Gamma Globulin
31 A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis Completed NCT00979654 Phase 2 Sifalimumab
32 Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis Recruiting NCT03529955 Phase 2 Apremilast 30mg
33 A Study In Adults With Moderate To Severe Dermatomyositis Recruiting NCT03181893 Phase 2 PF-06823859;Placebo Arm
34 Study of IFN-K in Dermatomyositis Recruiting NCT02980198 Phase 2
35 Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis Recruiting NCT02043548 Phase 2 tocilizumab;placebo
36 Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Recruiting NCT03267277 Phase 2 Sodium Thiosulfate
37 Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis Active, not recruiting NCT02466243 Phase 2 JBT-101;Placebo
38 Trial of IMO-8400 in Adult Patients With Dermatomyositis Active, not recruiting NCT02612857 Phase 2 IMO-8400 Dose Group 1;IMO-8400 Dose Group 2;Placebo
39 Basiliximab Treating Interstitial Pneumonia of CADM Not yet recruiting NCT03192657 Phase 2 Basiliximab;Calcineurin Inhibitors;Steroids
40 Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders Not yet recruiting NCT02418273 Phase 1, Phase 2 denosumab
41 Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis Terminated NCT01148810 Phase 2 BAF312;Placebo
42 A Pilot Study to Evaluate Topical Sodium Thiosulfate Therapy for Calcinosis Cutis Withdrawn NCT01918904 Phase 2 Sodium thiosulfate;Placebo
43 Evaluation of the Safety and Effectiveness of Tailored Transoral Incisionless Fundoplication (TIF) Using EsophyX for the Treatment of GERD Withdrawn NCT01025739 Phase 2
44 A Pilot Study of Etanercept in Dermatomyositis Completed NCT00112385 Phase 1 Etanercept;Placebo
45 A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis Completed NCT00533091 Phase 1
46 A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases Completed NCT02780674 Phase 1
47 Mycophenolate Mofetil in Systemic Sclerosis Completed NCT00433186 Phase 1 Mycophenolate Mofetil
48 Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders Completed NCT00010335 Phase 1
49 Study of Tofacitinib in Refractory Dermatomyositis Recruiting NCT03002649 Phase 1 Tofacitinib
50 Dermatomyositis and Polymyositis Registry Unknown status NCT01637064 Acthar

Search NIH Clinical Center for Dermatomyositis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: dermatomyositis

Genetic Tests for Dermatomyositis

Anatomical Context for Dermatomyositis

The Foundational Model of Anatomy Ontology organs/tissues related to Dermatomyositis:

19
Muscle Or

MalaCards organs/tissues related to Dermatomyositis:

41
Skin, Lung, Breast, Bone, T Cells, Heart, Colon

Publications for Dermatomyositis

Articles related to Dermatomyositis:

(show top 50) (show all 1417)
# Title Authors Year
1
Aberrant activation of type I interferon system may contribute to the pathogenesis of anti-MDA5 dermatomyositis. ( 29947075 )
2018
2
Coexistence of Dermatomyositis and Alopecia Areata: Insight into Pathogenesis. ( 29854645 )
2018
3
Extensive skin ulcers in a child with juvenile dermatomyositis. ( 29367373 )
2018
4
Aminoquinoline antimalarial therapy in dermatomyositis-are we missing opportunities with respect to comorbidities and modulation of extracutaneous disease activity? ( 29862243 )
2018
5
Current management of juvenile dermatomyositis in Germany and Austria: an online survey of pediatric rheumatologists and pediatric neurologists. ( 29925381 )
2018
6
The clinical application of tumor markers in the screening of malignancies and interstitial lung disease of dermatomyositis/polymyositis patients: A retrospective study. ( 29977547 )
2018
7
Targeted lipidomics analysis identified altered serum lipid profiles in patients with polymyositis and dermatomyositis. ( 29720222 )
2018
8
Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies. ( 29957268 )
2018
9
Development of practice and consensus-based strategies including a treat-to-target approach for the management of moderate and severe juvenile dermatomyositis in Germany and Austria. ( 29940960 )
2018
10
The Association Between Nailfold Capillary Density and Pulmonary and Cardiac Involvement in Medium- to Long-standing Juvenile Dermatomyositis. ( 29953739 )
2018
11
Panniculitis associated with amyopathic dermatomyositis. ( 29641712 )
2018
12
[<sup>18</sup>F]Fluorodeoxyglucose positron emission tomography/computed tomography for diagnosing polymyositis/dermatomyositis. ( 29805526 )
2018
13
Correlation between disease activity and serum ferritin in clinically amyopathic dermatomyositis with rapidly-progressive interstitial lung disease: a case report. ( 29338781 )
2018
14
Ground-glass opacity heralding invasive lung adenocarcinoma with prodromal dermatomyositis: a case report. ( 29415746 )
2018
15
Baseline peripheral blood neutrophil-to-lymphocyte ratio could predict survival in patients with adult polymyositis and dermatomyositis: A retrospective observational study. ( 29293605 )
2018
16
Malignancy in a retrospective cohort of 17 patients with Dermatomyositis or Polymyositis in southern Tunisia. ( 29791319 )
2018
17
Splicing variant of<i>WDFY4</i>augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. ( 29331962 )
2018
18
Genetic background may contribute to the latitude-dependent prevalence of dermatomyositis and anti-TIF1-I^ autoantibodies in adult patients with myositis. ( 29884237 )
2018
19
Intravenous immunoglobulin is an effective treatment for refractory cutaneous dermatomyositis. ( 29856076 )
2018
20
Scrotal calcinosis in an adult patient with amyopathic dermatomyositis. ( 29945258 )
2018
21
Cluster Analysis Using Anti-Aminoacyl-tRNA Synthetases and SS-A/Ro52 antibodies in Patients With Polymyositis/Dermatomyositis. ( 29933322 )
2018
22
The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease. ( 29325580 )
2018
23
Delayed recovery of limb muscle power after general anesthesia with cisatracurium in a dermatomyositis patient. ( 29980001 )
2018
24
Circulating plasma microRNA profiling in patients with polymyositis/dermatomyositis before and after treatment: miRNA may be associated with polymyositis/dermatomyositis. ( 29321815 )
2018
25
Role of the chemokine receptors CXCR3, CXCR4 and CCR7 in the intramuscular recruitment of plasmacytoid dendritic cells in dermatomyositis. ( 29366593 )
2018
26
Hyaluronic acid in dermatomyositis and polymyositis: relationship with disease and cutaneous lesions. ( 29641701 )
2018
27
Increased Levels of Soluble Programmed Death Ligand 1 Associate with Malignancy in Patients with Dermatomyositis. ( 29419471 )
2018
28
Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. ( 28993346 )
2018
29
Bosentan for Cutaneous Ulcers in Anti-MDA5 Dermatomyositis. ( 29344607 )
2018
30
Anti-MDA5 Antibody-Positive Dermatomyositis Presenting with Cellulitis-Like Erythema on the Mandible as an Initial Symptom. ( 29867431 )
2018
31
Association of Serum Soluble CD163 with Polymyositis and Dermatomyositis, Especially in Anti-MDA5 Antibody-positive Cases. ( 29657141 )
2018
32
Horizontal and vertical sections of scalp biopsy specimens from dermatomyositis patients with scalp involvement. ( 29409918 )
2018
33
Anti-aminoacyl tRNA Synthetase Antibody-Positive Clinically Amyopathic Dermatomyositis. ( 29346626 )
2018
34
Multiple target autoantigens on endothelial cells identified in juvenile dermatomyositis using proteomics. ( 29361142 )
2018
35
Ultrasound: A Potential Tool for Detecting of Fasciitis in Dermatomyositis and Polymyositis. ( 29496919 )
2018
36
Anti-transcription intermediary factor 1I^ antibody titer correlates with clinical symptoms in a patient with recurrent dermatomyositis associated with ovarian cancer. ( 29341447 )
2018
37
Recurrence of anti-MDA5 antibody-positive clinically amyopathic dermatomyositis after long-term remission: A case report. ( 29952940 )
2018
38
Clinical Images: Calcinosis of the mandible in dermatomyositis. ( 29579373 )
2018
39
JAK-STAT signaling pathway inhibition: a role for treatment of discoid lupus erythematosus and dermatomyositis. ( 29873082 )
2018
40
Dermatomyositis: Histopathologic findings of parakeratosis and dermal edema revisited. ( 29330862 )
2018
41
Efficacy and safety of cyclophosphamide treatment in severe juvenile dermatomyositis shown by marginal structural modelling. ( 29342499 )
2018
42
A Viral Polymyositis Masquerade: Life-Threatening Case of Juvenile Dermatomyositis Complicated by Systemic Capillary Leak Syndrome. ( 29720802 )
2018
43
Dermatomyositis: clinicopathological correlations. ( 29368856 )
2018
44
Musculoskeletal Manifestations of Non-RA Connective Tissue Diseases: Scleroderma, Systemic Lupus Erythematosus, Still's Disease, Dermatomyositis/Polymyositis, SjAPgren's Syndrome, and Mixed Connective Tissue Disease. ( 29672805 )
2018
45
Anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase autoantibody-positive necrotizing autoimmune myopathy with dermatomyositis-like eruption. ( 29346706 )
2018
46
Facial Calcinosis Cutis in a Woman with Paraneoplastic Dermatomyositis. ( 29598989 )
2018
47
Atorvastatin-Induced Dermatomyositis: Resolution With Change in Statin? ( 29424763 )
2018
48
Lipid-lowering agent-triggered dermatomyositis and polymyositis: a case series and literature review. ( 29027009 )
2018
49
Increased risk of venous thromboembolism associated with polymyositis and dermatomyositis: a meta-analysis. ( 29416342 )
2018
50
The effect of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis. ( 29703532 )
2018

Variations for Dermatomyositis

Expression for Dermatomyositis

Search GEO for disease gene expression data for Dermatomyositis.

Pathways for Dermatomyositis

Pathways related to Dermatomyositis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.7 MIR199B MIR21 MIR210 MIR214 MIR221 MIR222
2 11.03 MIR210 MIR221 MIR222
3 10.88 MIR221 MIR222
4 10.71 MIR146B MIR221 MIR222
5 10.7 MIR148A MIR148B

GO Terms for Dermatomyositis

Cellular components related to Dermatomyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.44 MIR132 MIR146B MIR148A MIR148B MIR199B MIR21

Biological processes related to Dermatomyositis according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of angiogenesis GO:0016525 9.8 MIR21 MIR214 MIR222 MIR34A
2 negative regulation of cell migration GO:0030336 9.78 MIR21 MIR214 MIR34A
3 positive regulation of protein kinase B signaling GO:0051897 9.77 MIR132 MIR199B MIR21 MIR221 MIR222
4 positive regulation of epithelial to mesenchymal transition GO:0010718 9.72 MIR21 MIR221 MIR222
5 positive regulation of angiogenesis GO:0045766 9.72 MIR132 MIR199B MIR21 MIR210 MIR99B
6 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.69 MIR214 MIR223 MIR34A
7 positive regulation of epithelial cell migration GO:0010634 9.65 MIR221 MIR222
8 positive regulation of cardiac muscle cell proliferation GO:0060045 9.64 MIR199B MIR222
9 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.64 MIR199B MIR21
10 negative regulation of sprouting angiogenesis GO:1903671 9.63 MIR221 MIR34A
11 positive regulation of G1/S transition of mitotic cell cycle GO:1900087 9.63 MIR221 MIR222
12 positive regulation of erythrocyte differentiation GO:0045648 9.62 MIR221 MIR222
13 positive regulation of vascular endothelial cell proliferation GO:1905564 9.62 MIR132 MIR21
14 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.61 MIR21 MIR221
15 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.6 MIR221 MIR222
16 positive regulation of connective tissue replacement GO:1905205 9.59 MIR214 MIR34A
17 positive regulation of axon regeneration GO:0048680 9.58 MIR221 MIR222
18 negative regulation by host of viral genome replication GO:0044828 9.58 MIR221 MIR222
19 positive regulation of endothelial cell differentiation GO:0045603 9.58 MIR199B MIR21 MIR99B
20 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.57 MIR21 MIR210
21 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.56 MIR221 MIR222
22 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.56 MIR21 MIR214 MIR221 MIR222
23 miRNA mediated inhibition of translation GO:0035278 9.55 MIR132 MIR21 MIR210 MIR221 MIR222
24 negative regulation of cell adhesion molecule production GO:0060354 9.54 MIR221 MIR222
25 negative regulation of TRAIL-activated apoptotic signaling pathway GO:1903122 9.52 MIR221 MIR222
26 positive regulation of Schwann cell migration GO:1900149 9.48 MIR221 MIR222
27 negative regulation of hematopoietic stem cell proliferation GO:1902034 9.46 MIR221 MIR222
28 positive regulation of Schwann cell proliferation involved in axon regeneration GO:1905046 9.43 MIR221 MIR222
29 gene silencing by miRNA GO:0035195 9.4 MIR132 MIR146B MIR148A MIR148B MIR199B MIR21
30 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.26 MIR21 MIR214 MIR223 MIR34A

Molecular functions related to Dermatomyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.4 MIR132 MIR146B MIR148A MIR148B MIR199B MIR21

Sources for Dermatomyositis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....